FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1521-1531 October 7, 2004 Number 15 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Wands, J. R. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The effectiveness of antiviral therapy in preventing disease progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown.

Methods Patients with chronic hepatitis B who had histologically confirmed cirrhosis or advanced fibrosis were randomly assigned in a 2:1 ratio to receive lamivudine (100 mg per day) or placebo for a maximum of five years. Of 651 patients, 436 were assigned to receive lamivudine and 215 to receive placebo. The primary end point was time to disease progression, defined by hepatic decompensation, hepatocellular carcinoma, spontaneous bacterial peritonitis, bleeding gastroesophageal varices, or death related to liver disease. An independent data and safety monitoring board monitored the progress of the study and performed interim analyses of the data.

Results We randomly assigned 651 patients (98 percent Asian and 85 percent male) to receive lamivudine or placebo. The study was terminated after a median duration of treatment of 32.4 months (range, 0 to 42) owing to a significant difference between treatment groups in the number of end points reached. End points were reached by 7.8 percent of the patients receiving lamivudine and 17.7 percent of those receiving placebo (hazard ratio for disease progression, 0.45; P=0.001). The Child–Pugh score increased in 3.4 percent of the patients receiving lamivudine and 8.8 percent of those receiving placebo (hazard ratio, 0.45; P=0.02), whereas hepatocellular carcinoma occurred in 3.9 percent of those in the lamivudine group and 7.4 percent of those in the placebo group (hazard ratio, 0.49; P=0.047). Genotypic resistance YMDD mutations developed in 49 percent of the patients treated with lamivudine, and the Child–Pugh score was more likely to increase in patients with these mutations than in the other patients treated with lamivudine (7 percent vs. <1 percent). Overall, 12 percent of the patients in the lamivudine group and 18 percent of the patients in the placebo group reported serious adverse events.

Conclusions Continuous treatment with lamivudine delays clinical progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis by significantly reducing the incidence of hepatic decompensation and the risk of hepatocellular carcinoma.

Source Information

From Chang Gung Memorial Hospital and University, Taipei, Taiwan (Y.-F.L.); Prince of Wales Hospital, Hong Kong (J.J.Y.S.); Singapore General Hospital, Singapore (W.C.C.); the Storr Liver Unit, Westmead Millennium Institute, and University of Sydney, Sydney, Australia (G.F.); National Taiwan University College of Medicine and University Hospital, Taipei (C.-Z.L.); Princess Margaret Hospital, Hong Kong (H.Y.); Siriraj Hospital, Bangkok, Thailand (T.T.); People's Hospital, Beijing (Q.-M.T.); GlaxoSmithKline, Singapore (K.S., J.S.); and GlaxoSmithKline, Greenford, United Kingdom (O.N.K., J.S.D., D.F.G.).

Address reprint requests to Professor Liaw at the Liver Research Unit, Chang Gung Memorial Hospital and University, 199 Tung Hwa North Rd., Taipei 105, Taiwan, or at liveryfl{at}so-net.net.tw.

Full Text of this Article

This article has been cited by other articles:

• Cescon, M., Cucchetti, A., Grazi, G. L., Ferrero, A., Vigano, L., Ercolani, G., Ravaioli, M., Zanello, M., Andreone, P., Capussotti, L., Pinna, A. D. (2009). Role of Hepatitis B Virus Infection in the Prognosis After Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis: A Western Dual-Center Experience. Arch Surg 144: 906-913 [Abstract] [Full Text]  
• Wong, V. W.-S., Sung, J. J.-Y. (2009). Antiviral therapy for chronic hepatitis B: are we doing any good to patients?. J Antimicrob Chemother 64: 223-226 [Abstract] [Full Text]  
• Scarsi, K. K., Darin, K. M. (2009). Chronic Hepatitis B Infection: Principles of Therapy. Journal of Pharmacy Practice 22: 359-387 [Abstract]  
• Wang, C.-S., Yao, W.-J., Chang, T.-T., Wang, S.-T., Chou, P. (2009). The Impact of Type 2 Diabetes on the Development of Hepatocellular Carcinoma in Different Viral Hepatitis Statuses. Cancer Epidemiol. Biomarkers Prev. 18: 2054-2060 [Abstract] [Full Text]  
• Chan, H. L.-Y., Wong, V. W.-S., Wong, G. L.-H., Chim, A. M.-L., Lai, L. H., Sung, J. J.-Y. (2009). Evaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma. J. Clin. Microbiol. 47: 1830-1836 [Abstract] [Full Text]  
• SHERMAN, M. (2009). Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleveland Clinic Journal of Medicine 76: S6-S9 [Abstract] [Full Text]  
• Kaiser, T., Moessner, J., Patel, K., McHutchison, J. G, Tillmann, H. L (2009). Life threatening liver disease during treatment with monoclonal antibodies. BMJ 338: b508-b508 [Full Text]  
• Shamliyan, T. A., MacDonald, R., Shaukat, A., Taylor, B. C., Yuan, J.-M., Johnson, J. R., Tacklind, J., Rutks, I., Kane, R. L., Wilt, T. J. (2009). Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference. ANN INTERN MED 150: 111-124 [Abstract] [Full Text]  
• Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., de Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., Manns, M., Kotzev, I., Tchernev, K., Buggisch, P., Weilert, F., Kurdas, O. O., Shiffman, M. L., Trinh, H., Washington, M. K., Sorbel, J., Anderson, J., Snow-Lampart, A., Mondou, E., Quinn, J., Rousseau, F. (2008). Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B. NEJM 359: 2442-2455 [Abstract] [Full Text]  
• Lai, C.-L., Yuen, M.-F. (2008). Chronic Hepatitis B -- New Goals, New Treatment. NEJM 359: 2488-2491 [Full Text]  
• Dienstag, J. L. (2008). Hepatitis B Virus Infection. NEJM 359: 1486-1500 [Full Text]  
• Llovet, J. M., Lok, A. (2008). Hepatitis B Virus Genotype and Mutants: Risk Factors for Hepatocellular Carcinoma. JNCI J Natl Cancer Inst 100: 1121-1123 [Full Text]  
• Singh, N. A., Reau, N. (2008). Management of hepatitis B virus. J Antimicrob Chemother 62: 224-228 [Abstract] [Full Text]  
• Lau, D. T.-Y., Bleibel, W. (2008). Review: Current status of antiviral therapy for hepatitis B. Therapeutic Advances in Gastroenterology 1: 61-75 [Abstract]  
• Lu, S.-N., Wang, J.-H., Chen, P.-F., Tung, H.-D., Tseng, P.-L., Hung, C.-H., Kee, K.-M., Chen, C.-H., Chang, K.-C., Lee, C.-M., Changchien, C.-S., Chen, Y.-D., Tsai, L.-S., Chen, T. H.-H. (2008). Community-Based Mass Ultrasonographic Screening of Hepatocellular Carcinoma among Thrombocytopenic Adults. Cancer Epidemiol. Biomarkers Prev. 17: 1813-1821 [Abstract] [Full Text]  
• Dusheiko, G, Antonakopoulos, N (2008). Current treatment of hepatitis B. Gut 57: 105-124 [Full Text]  
• Lai, C.-L., Gane, E., Liaw, Y.-F., Hsu, C.-W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E. J., Rasenack, J., Bzowej, N., Naoumov, N. V., Di Bisceglie, A. M., Zeuzem, S., Moon, Y. M., Goodman, Z., Chao, G., Constance, B. F., Brown, N. A., the Globe Study Group, (2007). Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. NEJM 357: 2576-2588 [Abstract] [Full Text]  
• Feld, J. J., Ghany, M. G. (2007). Evolution of Therapy for Chronic Hepatitis B: Progressing from the Simple to the Complex. ANN INTERN MED 147: 806-808 [Full Text]  
• Chan, H. L.Y., Heathcote, E. J., Marcellin, P., Lai, C.-L., Cho, M., Moon, Y. M., Chao, Y.-C., Myers, R. P., Minuk, G. Y., Jeffers, L., Sievert, W., Bzowej, N., Harb, G., Kaiser, R., Qiao, X.-J., Brown, N. A., and the 018 Study Group, (2007). Treatment of Hepatitis B e Antigen Positive Chronic Hepatitis with Telbivudine or Adefovir: A Randomized Trial. ANN INTERN MED 147: 745-754 [Abstract] [Full Text]  
• Price, N., Boxall, E. H. (2007). Treatment of children persistently infected with hepatitis B virus: seroconversion or suppression. J Antimicrob Chemother 60: 1189-1192 [Abstract] [Full Text]  
• Libbrecht, E., Doutreloigne, J., Van De Velde, H., Yuen, M.-F., Lai, C.-L., Shapiro, F., Sablon, E. (2007). Evolution of Primary and Compensatory Lamivudine Resistance Mutations in Chronic Hepatitis B Virus-Infected Patients during Long-Term Lamivudine Treatment, Assessed by a Line Probe Assay. J. Clin. Microbiol. 45: 3935-3941 [Abstract] [Full Text]  
• Thibault, V., Pichoud, C., Mullen, C., Rhoads, J., Smith, J. B., Bitbol, A., Thamm, S., Zoulim, F. (2007). Characterization of a New Sensitive PCR Assay for Quantification of Viral DNA Isolated from Patients with Hepatitis B Virus Infections. J. Clin. Microbiol. 45: 3948-3953 [Abstract] [Full Text]  
• Pungpapong, S., Kim, W. R., Poterucha, J. J. (2007). Natural History of Hepatitis B Virus Infection: An Update for Clinicians. Mayo Clin Proc. 82: 967-975 [Abstract] [Full Text]  
• Lai, C.-L., Yuen, M.-F. (2007). The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points. ANN INTERN MED 147: 58-61 [Abstract] [Full Text]  
• Lim, C. Y., Kowdley, K. V. (2007). Optimal duration of therapy in HBV-related cirrhosis. J Antimicrob Chemother 60: 2-6 [Abstract] [Full Text]  
• Koziel, M. J., Peters, M. G. (2007). Viral Hepatitis in HIV Infection. NEJM 356: 1445-1454 [Full Text]  
• Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., Papadimitrakopoulou, V. A., Lotan, R., Aggarwal, B. B., Bresalier, R. S., Kim, J., Arun, B., Lu, K. H., Thomas, M. E., Rhodes, H. E., Brewer, M. A., Follen, M., Shin, D. M., Parnes, H. L., Siegfried, J. M., Evans, A. A., Blot, W. J., Chow, W.-H., Blount, P. L., Maley, C. C., Wang, K. K., Lam, S., Lee, J. J., Dubinett, S. M., Engstrom, P. F., Meyskens, F. L. Jr., O'Shaughnessy, J., Hawk, E. T., Levin, B., Nelson, W. G., Hong, W. K., for the AACR Task Force on Cancer Prevention, (2006). Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward. Clin. Cancer Res. 12: 3661-3697 [Abstract] [Full Text]  
• Osborn, M. K., Lok, A. S. F. (2006). Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 57: 1030-1034 [Abstract] [Full Text]  
• Huo, T-I, Wu, J-C, Lee, S-D, Yuen, M-F, Lai, C-L (2006). Do baseline ALT levels predict complications of chronic hepatitis B? * Authors' reply. Gut 55: 745-746 [Full Text]  
• Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., Cross, A., DeHertogh, D., Wilber, R., Colonno, R., Apelian, D., the BEHoLD AI463022 Study Group, (2006). A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. NEJM 354: 1001-1010 [Abstract] [Full Text]  
• Lai, C.-L., Shouval, D., Lok, A. S., Chang, T.-T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., Colonno, R., Fernandes, L., the BEHoLD AI463027 Study Group, (2006). Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. NEJM 354: 1011-1020 [Abstract] [Full Text]  
• Hoofnagle, J. H. (2006). Hepatitis B -- Preventable and Now Treatable. NEJM 354: 1074-1076 [Full Text]  
• Pallier, C., Castera, L., Soulier, A., Hezode, C., Nordmann, P., Dhumeaux, D., Pawlotsky, J.-M. (2006). Dynamics of Hepatitis B Virus Resistance to Lamivudine. J. Virol. 80: 643-653 [Abstract] [Full Text]  
• Wong, S. N., Lok, A. S. F. (2006). Treatment of Hepatitis B: Who, When, and How?. Arch Intern Med 166: 9-12 [Full Text]  
• Bartlett, J. G. (2006). Update in Infectious Diseases. ANN INTERN MED 144: 49-56 [Full Text]  
• (2005). Additional Information. JAMA 294: E1-E3 [Full Text]  
• Sherman, M (2005). Predicting survival in hepatitis B. Gut 54: 1521-1523 [Full Text]  
• Gluud, C (2005). Mortality from cirrhosis: lack of progress over the last 35 years. Gut 54: 1523-1526 [Full Text]  
• Lok, A. S. (2005). The Maze of Treatments for Hepatitis B. NEJM 352: 2743-2746 [Full Text]  
• Stray, S. J., Bourne, C. R., Punna, S., Lewis, W. G., Finn, M. G., Zlotnick, A. (2005). A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc. Natl. Acad. Sci. USA 102: 8138-8143 [Abstract] [Full Text]  
• Kanwal, F., Gralnek, I. M., Martin, P., Dulai, G. S., Farid, M., Spiegel, B. M.R. (2005). Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis. ANN INTERN MED 142: 821-831 [Abstract] [Full Text]  
• Goedert, J. J. (2005). Preventing Infection-Associated Cancer: From Bench to Hillside. JNCI J Natl Cancer Inst 97: 245-246 [Full Text]  
• (2005). JournalScan. Gut 54: 168-168 [Full Text]  
• (2004). Lamivudine Delays Complications of Chronic Hepatitis B and Reduces Risk for Hepatocellular Carcinoma. JWatch Infect. Diseases 2004: 4-4 [Full Text]  
• (2004). New Antiviral Regimens for Chronic Hepatitis B. JWatch General 2004: 2-2 [Full Text]  
• Wands, J. R. (2004). Prevention of Hepatocellular Carcinoma. NEJM 351: 1567-1570 [Full Text]